Phase II trial of amonafide in central nervous system tumors: A Southwest Oncology Group Study

Sarah A. Taylor, Cathryn Rankin, Jeannette J. Townsend, Johnny B. Craig, Ralph B. Vance, Dilip L. Solank, Thomas D. Brown, Kurt Jaeckle

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Amonafide 300 mg/M2 was administered intravenously on a daily × 5 schedule to 27 eligible patients with recurrent or progressive central nervous system tumors. There were no objective responses. The most common toxicities were gastrointestinal, hematologic and neurologic. Further study of amonafide in patients with central nervous system malignancies is not indicated.

Original languageEnglish (US)
Pages (from-to)113-115
Number of pages3
JournalInvestigational New Drugs
Volume20
Issue number1
DOIs
StatePublished - Apr 6 2002

Keywords

  • Amonafide
  • Central nervous system tumors

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II trial of amonafide in central nervous system tumors: A Southwest Oncology Group Study'. Together they form a unique fingerprint.

  • Cite this

    Taylor, S. A., Rankin, C., Townsend, J. J., Craig, J. B., Vance, R. B., Solank, D. L., Brown, T. D., & Jaeckle, K. (2002). Phase II trial of amonafide in central nervous system tumors: A Southwest Oncology Group Study. Investigational New Drugs, 20(1), 113-115. https://doi.org/10.1023/A:1014488922368